Send the link below via email or IMCopy
Present to your audienceStart remote presentation
- Invited audience members will follow you as you navigate and present
- People invited to a presentation do not need a Prezi account
- This link expires 10 minutes after you close the presentation
- A maximum of 30 users can follow your presentation
- Learn more about this feature in our knowledge base article
Business Analysis - GlaxoSmithKline
Transcript of Business Analysis - GlaxoSmithKline
Alex Wagner GlaxoSmithKline (GSK) Introduction Conclusion Their headquarters for global pharmaceutical operations is in Brentford, United Kingdom.
Separated into 3 general categories: "Efficient with Significant Control"
One major way to save money and increase efficiency is to outsource.
Recent Contracts With GSK: GlaksoSmithKline & Outsourcing
“Technology underpins everything we do, whether it's in discovery, development, manufacturing or any of the commercial organizations”.
GSK Employee: 1994
Current Position: January 31, 2007
Approximately 97,000 Internal Users
300,000 Emails Per Day
Production and Delivery of Over 4 Billion Product Packs Information Management Pharmaceutical Industry
3 Major Competitors
Research and Development Strategic Decision Pharmaceutical Industry
Goals of GlaxoSmithKline
Strategic Decision Making
Projections for the Future Pharmaceutical Industry "Public and private organizations involved in the discovery, development, and manufacture of drugs and medications."
GSK provides medications, vaccines and consumer healthcare
Market Share: Pfizer 8.7%, GlaxoSmithKline 6.3%, Sanofi-Aventis 5.5%, Novartis 5%, and Other 74.4% Patents Expiration When patents expire, GSK's profits from that particular drug decreases dramatically Acquire GSK needs to continue to develop drugs to be patented Porter's Five Forces Buyer Power Low: Patented Products Supplier Power Low: Intellectual Property
High: FDA Control Threat of Substitute Products Low: Patented Products
High: Generic Brands Threat of New Entrants Low: Capital Costs Rivalry among Existing Competitors High: 3 Leading Companies Short and Long Term Goals By 2015: Reduce Carbon Footprint by 25%
Reduce Water Consumption by 20% By 2020: Absolute Zero Landfill Waste By 2050: Become "Carbon Neutral" GlaxoSmithKline Locations GSK: Expansions and Business Model Understanding Partnerships Expands Research Opportunities
Risk Disbursement GSK's Leadership Chief Executive Officer: Sir Andrew Witty GSK Employee: 1985
Current Position: 2008 Chief Financial Officer: Simon Dingemans 25 Years of Investment Banking Experience
Current Position: April 2011 Chairman, Research and Development: Moncef Slaoui PhD in Molecular Biology and Immunology
Current Position: June 2006 Chief Strategy Officer: David Redfern GSK Employee: 1994
Current Position: May 2008 Open Innovation Partnerships
Open Source Research
Open Source Facilities
Spain Open Lab Bill Louv: Chief Information Officer
Role of IT at GSK
Renewed 5 Year Contract
Signed 5 Year Contract
Signed 5 Year Contract Research and Development
Prescription Products GSK Realizes This Will Be a Challenge Return on Investment Opportunities and Risks External Conditions Research and Development Supply Chain
Inhalers (CFC's) gross profit margin: 73.23%
net profit margin: 19.21%
return on equity: 65.50%
return on assets: 12.81% Medicine is an industry that will be ever growing
"Open Innovation" Other key competitors
Health Care Reform Act 2014 -"Obamacare" Economy
Government "Research and development is an opportunity to invest and find new medicines"
"Sales are a reflection of research and development"
50% -- 50% GSK Layer's Of Organization Board of Directors Corporate Executive Team Company Secretary Audit and Risk Committee Remuneration Committee Nominations Committee Finance Committee Corporate Responsibility Committee Corporate Administration and Transactions Committee Carbon Neutral Value Chain by 2050
Benefits: in reduced distribution, energy, and material costs
80% of Emmisions Found In:
In 2011, GSK earned the Carbon Trust’s Global Climate Change Certification
Strategic Grid save $160 million a year by 2020 Food and Drug Administration Phase One Phase Two Phase Three Drug given to healthy individuals Increases group size
Testing on ill patients
Placebo test Greatest amount of ill patients
FDA may still deny approval